Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

07 July 2014 : Original article  

Early Conversion from Twice-Daily Tacrolimus to Once-Daily Extended Formulation in Renal Transplant Patients Before Hospital Discharge

Martin JannotABDFG, Ingrid MassonE, Eric AlamartineE, Christophe MariatACDEF

DOI: 10.12659/AOT.890262

Ann Transplant 2014; 19:320-324

Abstract

BACKGROUND: Although the once-daily formulation of tacrolimus (ADVAGRAF™) is approved in renal transplantation to be used immediately after surgery, conventional twice-daily formulation offers better flexibility to adjust the dosage of tacrolimus during the initial period of transplantation.

MATERIAL AND METHODS: We retrospectively report here our initial experience with a strategy of an early conversion from PROGRAF™ to ADVAGRAF™ before hospital discharge.

RESULTS: Forty-eight de novo renal transplant recipients were started on PROGRAF™ and then switched to ADVAGRAF™ after a median time of 11 days and 4.5 days, respectively, before discharge. In terms of tacrolimus exposure, great inter-individual heterogeneity was noted, with 56% of patients experiencing a clinically significant modification in post-switch tacrolimus blood trough levels. Modification in post-switch drug exposure was poorly predicted by change in tacrolimus daily dosage. Six-month post-transplant outcome was similar in patients converted to ADVAGRAF™ to that of patients who had remained on PROGRAF™ during the same period of time. Our data suggest that an early conversion from PROGRAF™ to ADVAGRAF™ during the hospital stay may be safely undertaken, provided tacrolimus exposure is tightly monitored in patients.

CONCLUSIONS: This strategy might represent an alternative to the immediate post-transplant introduction of ADVAGRAF™ and needs to be clinically validated in large-scale controlled trials.

Keywords: Drug Monitoring, immunosuppresive agent, Kidney Transplantation, Tacrolimus

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358